Lupus Therapeutics Market

Increasing Lupus Prevalence and Number of Research & Development Activities to Fuel Growth of Lupus Therapeutics Market

The Lupus Therapeutics Market is valued at USD 4.6  Bn in 2026 and is projected to reach USD 7.1  Bn,  growing at a CAGR of 7% by 2033.The rising prevalence of lupus disorders worldwide is one of the most important factors influencing the growth of the global lupus therapeutics market. According to an article published in the Lupus Science and Medicine journal in April 2021, the incidence and prevalence of Systemic Lupus Erythematosus (SLE) in Europe in 2020 were estimated to be around 0.3 to 5.1 per 100 000 per year and 6.5 to 85 per 100 000 population, respectively.

Since COVID-19 is linked to lupus, the COVID-19 pandemic is predicted to have a beneficial impact on the overall growth of the lupus treatments industry. According to a paper published in the Journal of Medical Case Reports in January 2021, the link between COVID-19 and lupus has yet to be established, but it suggests that COVID-19 could be a potential agent that causes systemic lupus erythematous by creating autoantibodies. The same source also cites a case report of a 39-year-old Iranian man who was the first to develop SLE after being exposed to COVID-19.

The market's expansion is being fuelled by an increase in the number of R&D activities. This will provide beneficial opportunities for the growth of the lupus therapeutic market. Additionally, rising drug approvals and launches will accelerate the market's growth rate. Furthermore, rising investment in the development of advanced technologies, as well as an increase in the number of emerging markets, will provide beneficial opportunities for the growth of the lupus therapeutic market during the forecast period.  For instance, in November 2021, AstraZeneca, a biopharmaceutical company announced positive results from its TULIP Phase 3 clinical trial programme (focused on determining the efficacy and safety of Anifrolumab), stating that Saphnelo (anifrolumab), a human monoclonal antibody, reduced SLE more than standard therapy alone.

Increasing Approvals of Clinical Trials for Systemic Lupus Erythematous (SLE) to Fuel Lupus Therapeutics Market Growth

The systemic lupus erythematous (SLE) category is predicted to account for the biggest market share due to increased approvals of clinical trials for developing SLE treatments. The autoimmune inflammatory illness systemic lupus erythematous (SLE) affects various organs and has a wide range of clinical symptoms. SLE is a type of lupus that affects the joints, skin, brain, lungs, kidneys, and blood vessels by causing tissue damage in the organs involved. The global lupus therapeutics market's manufacturers and players provide treatment therapeutics for a variety of lupus illnesses, including SLE (systemic lupus erythematous).

Growing Emphasis of Major Key Players in North America to Drive Growth Lupus Therapeutics Market

North America dominates the lupus therapeutic market due to the increasing prevalence of lupus in this region. Furthermore, the growing emphasis of major key players on novel technology will accelerate the market's growth rate in this region. Rising investments in high-end, technologically advanced healthcare infrastructure and facilities in developed economies are expected to fuel growth and development in the global lupus therapeutics market in the coming years. According to the Lupus Foundation of America, the year 2019 saw the growth of several companies for lupus treatment, including GSK and Aurinia Pharmaceuticals Inc.

Moreover, the rising prevalence of lupus disorders worldwide is one of the most important factors influencing the growth of the global lupus therapeutics market. For instance, nearly 1.5 million people in the US have some form of lupus, with SLE accounting for 70% of cases, and more than 90% of those diagnosed are women in their adolescent and adult years.

Asia-Pacific is expected to grow during the forecast period due to the region's growing population and rising healthcare expenditure. The growing number of research and drug development as well as drug discovery projects undertaken by industry participants is also influencing the growth of the global lupus therapeutics market. In December 2021, After receiving approval from the Drugs Controller General of India, Biocon Biologics Limited, a subsidiary of the Indian-based biotechnology company Biocon, announced that it has begun a clinical study for its drug Itolizumab for the treatment of Lupus Nephritis. SLE causes Lupus Nephritis, a kidney disease.

Global Lupus Therapeutics Market: Competitive Landscape

Companies in the market are introducing new products alongside initiation collaborations, alliances and partnership agreements. For instance, in January 2022, BenevolentAI, a clinical-stage AI drug discovery business based in the United Kingdom, stated that its collaboration with AstraZeneca for the development of therapeutic medications for the treatment of systemic lupus erythematous and heart failure has been expanded (HF). On the other hand, in December 2020, GlaxoSmithKline plc, a pharmaceutical firm based in the United Kingdom, announced that their medicine BENLYSTA (belimumab) has been approved by the United States Food and Drug Administration (FDA) for use in conjunction with conventional therapy in adult patients. SLE-related active lupus nephritis (LN) is a kidney condition caused by SLE.

A few of the players in the lupus therapeutics market include 

• GSK plc
• AstraZeneca PLC
• Aurinia Pharmaceuticals Inc.
• Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Sanofi S.A.
• Novartis AG
• Eli Lilly and Company
• Bristol Myers Squibb Company
• AbbVie Inc.
• Amgen Inc.
• Biogen Inc.
• Johnson & Johnson
• UCB S.A.
• Viatris Inc.

Global Lupus Therapeutics Market is Segmented as Below:

By Disease Type

• Systemic Lupus Erythematosus
• Cutaneous Lupus Erythematosus
• Drug-induced Lupus
• Neonatal Lupus
• Lupus Nephritis
• Others

By Drug Class

• Corticosteroids
• Antimalarials
• Immunosuppressants
• Biologics
• Nonsteroidal Anti-inflammatory Drugs
• B-cell Inhibitors
• Calcineurin Inhibitors
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

By End User

• Hospitals
• Specialty Clinics
• Rheumatology Clinics
• Dermatology Clinics
• Ambulatory Surgical Centers
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa